First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
Telix announces that the first patient has been dosed in the Company’s PSMA-targeting ‘ProstACT’ therapeutic program.
Telix Completes A$175 Million Placement and Launches A$25 Million SPP
Telix announces a successful $175 million institutional placement and launches Share Purchase Plan to raise up to $25 million.
Activities Report and Appendix 4C for December 2021 Quarter
Telix provides its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2021.
Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
Telix is pleased to announce a clinical data access agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI) relating to a prospective clinical trial investigating the use of O-(2-[18F]fluoroethyl)-L-tyrosine or 18F-FET to image glioblastoma patients with positron emission tomography (PET) (FET-PET). 18F-FET is under development by Telix (referred to as TLX101-CDx) as a complementary diagnostic agent to its TLX101 glioblastoma therapeutic candidate.
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
Telix announces that a first patient has been dosed in the ‘PERTINENCE’ Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder cancer
FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®
TRALA Study of TLX66 in AL-Amyloidosis Presented at ASH 2021
Telix is pleased to announce the first peer-reviewed results from the Phase I/IIa TRALA (Targeted Radiotherapy for AL Amyloidosis) study of the Company’s bone marrow conditioning investigational candidate TLX66 (90Y-besilesomab) in patients with Systemic Amyloid Light Chain Amyloidosis (AL-Amyloidosis), presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain
Telix announces agreement with NUCLIBER S.A. for the distribution of Telix’s prostate cancer investigational imaging product, Illuccix® in Spain.
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
The Brazilian Health Regulatory Agency has granted an exceptional authorisation for Illuccix® (TLX591-CDx), Telix’s lead prostate cancer imaging product.
First Telix and Duchembio Joint Symposium – Emergence of PSMA-PET Imaging in South Korea
With our partner, Duchembio, we are pleased to present a first joint symposium on 68Ga-PSMA-PET prostate cancer imaging in Korea.